science
ITM and Lumara Bio Announce Real-World Re-treatment Data and Dosimetry Results from COMPETE for ...
Investigator-led SwissNET registry analysis showed longer real-world progression-free and overall survival for patients re-treated with 177Lu-edotreotide compared to those receiving non-radiopharmaceutical systemic therapyPhase 3 COMPETE trial dosimetry analysis demonstrated favorable tumor-to-kidney absorbed dose ratio with low intra-patient variability
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Mouse study reveals magnetic nanoparticles' potential for ectopic pregnancy diagnosis and treatment
Phys.org
Wood beneath German lake may reveal buildings 3,000 years older than region's first farms
Phys.org
Seventeen K-Pop Robots Take Over Rockefeller Center, One Demands to Be Called a Soul
Hoodline
Four Sets of Abstract Moral Systems
Overcoming Bias Economics Blog
A home for ‘Inspiration': See the space shuttle mockup's future Downey building
Nbc Los Angeles